Non-Hodgkin Lymphoma Clinical Trials in Boston, Massachusetts

13 studies are recruiting for non-hodgkin lymphoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

   This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Research Site, Boston, Massachusetts

   Locations

   39 in total

   Run by

   AstraZeneca

   See if you can join NCT06137144 on ClinicalTrials.gov

2. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

3. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

4. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

   This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   11 in total

   Run by

   Miltenyi Biomedicine GmbH

   See if you can join NCT06116110 on ClinicalTrials.gov

5. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

   This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07020533 on ClinicalTrials.gov

6. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov

7. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

8. CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

   This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclopho…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Marcela V. Maus, M.D.,Ph.D.

   See if you can join NCT06026319 on ClinicalTrials.gov

9. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   DFCI/BWH Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

10. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

    The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    38 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876649 on ClinicalTrials.gov

11. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    36 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06876662 on ClinicalTrials.gov

12. Epco, Zanu, Ritux for R/R FL or MZL

    The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Reid Merryman, MD

    See if you can join NCT06563596 on ClinicalTrials.gov

13. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    36 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov